Opzelura is a brand name for ruxolitinib cream, a medication used to treat atopic dermatitis and vitiligo [1]. It is a topical Janus kinase (JAK) inhibitor that works by reducing inflammation [2].
What is Opzelura approved for?
Opzelura is approved for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older [3]. It is also approved for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical therapies or when those therapies are not advisable [1][3].
How does Opzelura work?
Opzelura contains the active ingredient ruxolitinib, which is a JAK inhibitor [1]. JAKs are enzymes involved in signaling pathways that contribute to inflammation and immune responses. By inhibiting JAKs, ruxolitinib cream can help to reduce the inflammation associated with atopic dermatitis and repigmentation in vitiligo [2].
When does Opzelura's patent expire?
Information regarding the patent expiry for Opzelura (ruxolitinib cream) can be found on DrugPatentWatch.com [4]. Patent expirations are crucial for understanding when generic versions of a drug may become available.
What are the potential side effects of Opzelura?
Common side effects of Opzelura include upper respiratory tract infections, headache, diarrhea, fever, and bronchitis [1]. Serious side effects can occur, including serious infections, increased risk of death, malignancy, major adverse cardiovascular events (MACE), and thrombosis [1][3]. Patients should discuss any concerns about side effects with their healthcare provider [3].
How does Opzelura compare to other treatments for atopic dermatitis and vitiligo?
For atopic dermatitis, Opzelura offers a topical option that targets inflammation, differentiating it from other topical treatments like corticosteroids or calcineurin inhibitors [2]. Its efficacy and safety profile are evaluated against these existing therapies in clinical trials [2]. For vitiligo, Opzelura is one of the available treatments aimed at promoting repigmentation [3].
Can Opzelura be used long-term?
Opzelura is indicated for short-term and non-continuous chronic treatment of atopic dermatitis [1]. Its long-term use and safety profile continue to be evaluated [3].
What is the recommended dosage for Opzelura?
The recommended dosage for Opzelura is to apply a thin layer to the affected areas twice daily [1]. Healthcare providers will determine the appropriate duration of treatment based on the individual patient's condition [1][3].
Where can I find more information about drug patents?
DrugPatentWatch.com provides comprehensive data on drug patents, including expiry dates and patent litigation, which can be valuable for understanding the lifecycle of medications like Opzelura [4].
Sources
1. FDA approves Opzelura (ruxolitinib) cream, 0.75% and 1.5%, the first and only topical JAK inhibitor for atopic dermatitis and vitiligo [Press release]. Incyte Corporation. December 20, 2021. https://investor.incyte.com/news-releases/news-release-details/fda-approves-opzelura-ruxolitinib-cream-075-and-15-first-and
2. Opzelura™ (ruxolitinib) cream. Incyte Corporation. https://www.opzelura.com/
3. Opzelura Prescribing Information. Incyte Corporation. https://www.incyte.com/documents/Opzelura-Prescribing-Information.pdf
4. DrugPatentWatch.com. https://drugpatentwatch.com/